Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $361.59 (market cap $9.55B), while Direxion Daily FTSE China Bull 3x Shares trades at $27.6. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals.
| BIO | YINN | |
|---|---|---|
Market Cap | $9.55B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $362.08 | $56.62 |
52-Week Low | $241.71 | $21.45 |
Enterprise Value | $9.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $362.08, up 1.64% today, with a bullish technical signal and strong institutional interest. The stock is near its consensus price target of $350, with a high target of $390. Recent Q2 2026 earnings beat expectations at $2.62 EPS versus $1.75 expected, though revenue remains flat year-over-year. Operating cash flow improved to $532.20M in 2025, and net income swung to a positive $759.90M after losses in prior years, signaling a turnaround.
The outlook is cautiously optimistic, supported by analyst consensus (53.85% buy ratings) and improving profitability. Key risks include high valuation (P/E 44.1) and reliance on stable government and defense sectors. Upside potential exists if earnings growth continues, but investors should monitor competitive pressures and macroeconomic impacts on research spending.
YINN, a leveraged ETF tracking the FTSE China Bull 3x index, trades at $29.01, down 3.53% on the day amid a bearish technical signal. The overall technical outlook is bearish with moving averages indicating selling pressure, though oscillators are neutral. Recent news highlights China's economic stabilization efforts and AI sector investments, while the ETF's structure amplifies risks from market volatility and geopolitical tensions.
The outlook for YINN is cautious due to its leveraged exposure to Chinese equities, which face regulatory and economic headwinds. Investment opportunities exist if Chinese markets rebound, but risks include high volatility decay and US-China trade frictions. Investors should weigh the potential for amplified gains against significant downside exposure in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
